A medical technology, services, and solutions company based in Dublin, Ireland, Medtronic Inc (MDT) stock was down -22.42% to $91.37 in the extended-hours session.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
What the Company does.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Medtronic has helped millions of people relieve pain, improve their health, and extend their lives. More than 90,000 Medtronic employees across the globe serve doctors, hospitals, and patients in more than 150 countries. Aiming to take healthcare Further, Together, the company collaborates with stakeholders around the world.
Read More
What’s the News?
Medtronic plc (NYSE: MDT), has announced that the first patient has enrolled in its ADAPT-PD study designed to assess the safety and efficacy of deep brain stimulation therapy for Parkinson’s disease (PD). The Percept PC device includes an investigational feature known as adaptive deep brain stimulation, which may be enabled if approved by the FDA. This study uses an investigational feature of brain stimulation to provide therapy, based on a patient’s clinical state, to manage Parkinson’s disease symptoms.
This randomized trial will occur across 12 sites at leading Movement Disorders research facilities in North America, Europe, and Canada. There will be 36 subjects assessed over 15 months.
As reported in the patient log, the primary outcome of ADAPT-PD contrasts regular continuous DBS (cDBS) to aDBS for hours of ‘On’ time without disrupting dyskinesias, a measure of treatment effectiveness versus side effects. In the analysis, eligible participants will receive cDBS at baseline, followed by a randomized blinded assessment of two distinct aDBS algorithms.
According to the Parkinson’s Foundation, over 10 million individuals live with Parkinson’s disease globally. Although the course of symptoms is identical, the various condition also varies from one patient to another. People with PD can experience trembling, slow motion (bradykinesia), limbs’ rigidity, and gait and balance problems.
Conclusion
So, what’s to blame for the drop in stock price? Honestly, it is hard to answer, other than “restless investors,” who are not impressed by the news.